Profile of T cell recognition of HIV type 1 consensus group M gag and nef peptides in a clade A1- and D-infected Ugandan population

AIDS Research and Human Retroviruses

Volumn 28, Issue 4, 2012, Pages 384-392

  Serwanga, Jennifer ^a   Mugaba, Susan ^a   Pimego, Edward ^a   Nanteza, Bridget ^a   Lyagoba, Fred ^a   Nakubulwa, Susan ^a   Heath, Laura ^b   Nsubuga, Rebecca N ^a   Ndembi, Nicaise ^a   Gotch, Frances ^c   Kaleebu, Pontiano ^a,d  

^a AIDS   (Uganda)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EPITOPE; GAG PEPTIDE; GAMMA INTERFERON; NEF PEPTIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MALE; MOLECULAR RECOGNITION; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE; UGANDA; VIRUS LOAD;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AIDS VACCINES; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; INTERFERON-GAMMA; MALE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECEPTORS, INTERFERON; T-LYMPHOCYTES; UGANDA; VIRAL LOAD;

EID: 84859189763     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0175     Document Type: Article

References (48)

1. Lynch RM, Shen T, Gnanakaran S, and Derdeyn CA: Appreciating HIV type 1 diversity: Subtype differences in Env. AIDS Res Hum Retroviruses 2009;25(3):237-248.
2. McCutchan FE: Global epidemiology of HIV. J Med Virol 2006;78(Suppl 1):S7-S12.
3. Taylor BS, Sobieszczyk ME, McCutchan FE, and Hammer SM: The challenge of HIV-1 subtype diversity. N Engl J Med 2008;358(April 10):1590-1602.
4. Neogi U, Sood V, Banerjee S, et al.: Global HIV-1 molecular epidemiology with special reference to genetic analysis of HIV-1 subtypes circulating in North India: Functional and pathogenic implications of genetic variation. Indian J Exp Biol 2009;47(6):424-431.
5. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25(5):679-689.
6. Brander C, Frahm N, and Walker BD: The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 2006;18(4):430-437.
7. Fischer W, Liao HX, Haynes BF, Letvin NL, and Korber B: Coping with viral diversity in HIV vaccine design: A response to Nickle et al. PLoS Comput Biol 2008;4(1):e15.
8. Gao F, Weaver EA, Lu Z, et al.: Antigenicity and immuno-genicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005;79(2): 1154-1163.
9. Nickle DC, Rolland M, Jensen MA, et al.: Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 2007; 3(4):e75.
10. Weaver EA, Lu Z, Camacho ZT, et al.: Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 2006;80(14):6745-6756.
11. Barouch DH, O'Brien KL, Simmons NL, et al.: Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16(3): 319-323.
12. Santra S, Liao HX, Zhang R, et al.: Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010;16(3):324-328.
13. Rolland M, Jensen MA, Nickle DC, et al.: Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol 2007;81(16): 8507-8514.
14. Gao F, Korber BT, Weaver E, et al.: Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004;3(4 Suppl):S161-168.
15. Kothe DL, Li Y, Decker JM, et al.: Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006;352(2):438-449.
16. Rolland M, Nickle DC, and Mullins JI: HIV-1 group M conserved elements vaccine. PLoS Pathog 2007;3(11):e157.
17. * allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naive Ugandans. PLoS One 2009;4(1):e4188.
18. Ngandu NG, Bredell H, Gray CM, Williamson C, and Seoighe C: CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs. AIDS Res Hum Retro-viruses 2007;23(8):1033-1041.
19. Deng W, Nickle DC, Learn GH, Maust B, and Mullins JI: ViroBLAST: A stand-alone BLAST web server for flexible queries of multiple databases and user's datasets. Bioinfor-matics 2007;23(17):2334-2336.
20. de Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21(19):3797-3800.
21. Lole KS, Bollinger RC, Paranjape RS, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of inter-subtype recombination. J Virol 1999;73(1):152-160.
22. Edgar RC: MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004;32(5): 1792-1797.
23. UNAIDS report on the Global epidemic, 2010.
24. Kiwanuka N, Laeyendecker O, Quinn TC, et al.: HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS 2009;23(18):2479-2484.
25. Kiwanuka N, Laeyendecker O, Robb M, et al.: Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008;197(5): 707-713.
26. McKnight A and Aasa-Chapman MM: Clade specific neutralising vaccines for HIV: An appropriate target? Curr HIV Res 2007;5(6):554-560.
27. Gao F, Liao HX, Hahn BH, et al.: Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 2007;5(6):572-577.
28. Frahm N, Nickle DC, Linde CH, et al.: Increased detection of HIV-specific T cell responses by combination of central se- quences with comparable immunogenicity. AIDS 2008;22(4): 447-456.
29. Bansal A, Gough E, Ritter D, et al.: Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients. AIDS 2006;20(3):353-360.
30. Rutebemberwa A, Currier JR, Jagodzinski L, et al.: HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. AIDS 2005;19(11):1165-1172.
31. Yang OO: Candidate vaccine sequences to represent intra-and inter-clade HIV-1 variation. PLoS One 2009;4(10):e7388.
32. Barouch DH: Challenges in the development of an HIV-1 vaccine. Nature 2008;455(7213):613-619.
33. Johnston MI: An HIV vaccine-evolving concepts. N Engl J Med 2007;356(20):2073-2081.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-2220.
35. Wang YE, Li B, Carlson JM, et al.: Protective HLA class I alleles that restrict acute-phase CD8 + T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol 2009;83(4):1845-1855.
36. Letourneau S, Im EJ, Mashishi T, et al.: Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007;2(10):e984.
37. Li F, Finnefrock AC, Dubey SA, et al.: Mapping HIV-1 vaccine induced T-cell responses: Bias towards less-conserved regions and potential impact on vaccine efficacy in the Step Study. PLoS One 2011;6(6):e20479.
38. Baker BM, Block BL, Rothchild AC, and Walker BD: Elite control of HIV infection: Implications for vaccine design. Expert Opin Biol Ther 2009;9(1):55-69.
39. Emu B, Sinclair E, Hatano H, et al.: HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008;82(11):5398-5407.
40. *5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 2009;83(6):2743-2755.
41. Koup RA and Ho DD: Shutting down HIV. Nature 1994;370(6489):416.
42. Brockman MA, Brumme ZL, Brumme CJ, et al.: Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 2010;84(22):11937-11949.
43. Betts MR, Nason MC, West SM, et al.: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8 + T cells. Blood 2006;107(12):4781-4789.
44. Hansen SG, Vieville C, Whizin N, et al.: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15(3):293-299.
45. Betts MR, Exley B, Price DA, et al.: Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 2005;102(12):4512- 4517.
46. Altfeld M, Addo MM, Shankarappa R, et al.: Enhanced de-tectionofhuman immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003;77(13):7330-7340.
47. Buchbinder SP, Mehrotra DV, Duerr A, et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-1893.
48. Gilbert PB, Rossini AJ, Shankarappa R. Two sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics 2005;61(1):106-117.